ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Diltiazem: Drug information

Diltiazem: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Diltiazem: Patient drug information" and "Diltiazem: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Cardizem;
  • Cardizem CD;
  • Cardizem LA;
  • Cartia XT;
  • Dilt-XR;
  • Matzim LA;
  • Taztia XT;
  • Tiadylt ER;
  • Tiazac
Brand Names: Canada
  • AA-Diltiaz;
  • ACT Diltiazem CD;
  • ACT Diltiazem T;
  • APO-Diltiaz CD;
  • Cardizem CD [DSC];
  • Diltiazem CD;
  • DilTIAZem T;
  • Diltiazem TZ [DSC];
  • Diltiazem-CD [DSC];
  • JAMP Diltiazem T;
  • JAMP-dilTIAZem CD;
  • MAR-Diltiazem CD;
  • MAR-Diltiazem T;
  • Pharma-Diltiaz;
  • PMS-Diltiazem CD [DSC];
  • PRO-Diltiazem CD;
  • SANDOZ Diltiazem CD [DSC];
  • SANDOZ Diltiazem T [DSC];
  • TEVA dilTIAZem XC;
  • TEVA-Diltazem [DSC];
  • TEVA-Diltiazem CD;
  • TEVA-Diltiazem HCl ER;
  • Tiazac;
  • Tiazac XC
Pharmacologic Category
  • Antianginal Agent;
  • Antiarrhythmic Agent, Class IV;
  • Antihypertensive;
  • Calcium Channel Blocker;
  • Calcium Channel Blocker, Nondihydropyridine
Dosing: Adult

Dosage guidance:

Safety: Avoid in patients taking a beta-blocker or who have heart failure with reduced ejection fraction, sinus node dysfunction, or second- or third-degree atrioventricular block unless a functioning pacemaker has been placed.

Angina

Angina:

Chronic stable angina (alternative agent): Note: A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a calcium channel blocker (typically a dihydropyridine [eg, amlodipine]) may be added with close monitoring of heart rate; diltiazem may be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (Ref).

Immediate release: Oral: Initial: 30 mg 4 times daily; increase as needed at 1- to 2-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 3 to 4 divided doses (Ref).

12-hour (twice-daily) formulations (off label): Oral: Initial: 60 mg twice daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 2 divided doses (Ref).

24-hour (once-daily) formulations: Oral: Initial 120 to 180 mg once daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day (Ref).

Vasospastic angina: Note: May use alone or in combination with nitrates (Ref).

Immediate release: Oral: Initial: 30 mg 4 times daily; increase as needed at 1- to 2-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 3 to 4 divided doses.

12-hour (twice-daily) formulations (off label): Oral: Initial: 60 mg twice daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 2 divided doses (Ref).

24-hour (once-daily) formulations: Oral: Initial: 120 to 180 mg once daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day (Ref).

Chest pain associated with cocaine ingestion, with or without evidence of acute coronary syndrome (off-label use) : Note: Adjunct or alternative to nitroglycerin.

IV: Bolus: Initial: 0.25 mg/kg (actual body weight) over 2 minutes (average dose: 20 mg); may repeat after 15 minutes if needed (Ref).

Atrial fibrillation/flutter, rate control

Atrial fibrillation/flutter, rate control: Note: For rate control in hemodynamically stable patients. Do not use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (Ref).

Acute ventricular rate control:

IV: Bolus dose: 0.25 mg/kg (actual body weight) over 2 minutes (average dose: 20 mg; if hypotension is a concern, some experts administer a lower bolus of 5 to 15 mg); if rate control is insufficient after 15 minutes, a repeat bolus dose of 0.35 mg/kg over 2 minutes may be given (average dose: 25 mg). Patients who respond after 1 or 2 bolus doses can be started on a continuous infusion (Ref).

IV: Continuous infusion following bolus(es): Initial: 5 to 10 mg/hour; infusion rate may be increased in 5 mg/hour increments according to ventricular response, up to a maximum of 15 mg/hour. Note: When increasing the infusion rate, an additional bolus dose can be used to provide more immediate onset. In general, the use of a continuous infusion >24 hours or >15 mg/hour is not recommended due to potential for drug accumulation (Ref). See conversion section below to switch from IV infusion to oral.

Chronic ventricular rate control (off-label use):

Immediate release: Oral: Initial: 30 mg 4 times daily; increase as needed to achieve ventricular rate control; usual dose: 120 to 480 mg/day in 3 or 4 divided doses (Ref).

Extended release: Oral: Initial: 120 mg once daily or in 2 divided doses depending on formulation; increase as needed to achieve ventricular rate control; usual dose: 120 to 480 mg/day (Ref).

Hypertension

Hypertension (alternative agent): Note : Reserve nondihydropyridine calcium channel blockers for patients with a relevant comorbidity (eg, rate control in atrial fibrillation or flutter) (Ref). For patients who warrant combination therapy (BP >20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, thiazide diuretic) (Ref).

12-hour (twice-daily) formulations: Oral: Initial: 60 to 120 mg twice daily; increase dose as needed after ~7 to 14 days; usual dose: 240 to 360 mg/day in 2 divided doses.

24-hour (once-daily) formulations: Oral: Initial: 120 to 240 mg once daily; increase dose as needed after ~7 to 14 days; usual dose: 120 to 360 mg once daily (Ref).

Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic

Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic (alternative agent) (off-label use): Note: A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, diltiazem may be added with close monitoring of heart rate; diltiazem may be used as an alternative therapy if beta-blockade cannot be tolerated (Ref).

Oral: Initial: 120 to 180 mg once daily or in divided doses depending on the drug formulation; usual effective dose: 240 to 360 mg/day; maximum dose: 480 mg/day (Ref).

Pulmonary arterial hypertension, group 1

Pulmonary arterial hypertension, group 1 (alternative agent) (off-label use): Note: Only used for group 1 pulmonary arterial hypertension patients with a positive vasoreactivity test and under the care of a pulmonary hypertension specialist (Ref).

12-hour (twice-daily) formulations: Oral: Initial: 60 mg every 12 hours; titrate gradually, with close hemodynamic monitoring; reported daily dose range: 120 to 720 mg/day in 2 divided doses (Ref).

24-hour (once-daily) formulations: Oral: Initial: 120 mg once daily; titrate gradually, with close hemodynamic monitoring; reported daily dose range: 120 to 720 mg/day (Ref).

Supraventricular tachycardia

Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifocal atrial tachycardia) (alternative agent): Note: For hemodynamically stable patients if vagal maneuvers and/or adenosine are unsuccessful. Do not use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (Ref).

Acute treatment:

IV: Bolus dose: 0.25 mg/kg (actual body weight) over 2 minutes (average dose: 20 mg); if response is insufficient after ≥15 minutes, a repeat bolus dose of 0.35 mg/kg over 2 minutes may be given (average dose: 25 mg). If bolus(es) do not terminate the arrhythmia, consider alternative therapy.

Chronic maintenance (off-label use):

Immediate release: Oral: Initial: 30 mg 4 times daily; increase as needed for heart rate control; usual effective dose: 360 mg/day in divided doses (Ref).

Extended release: Oral: Initial: 120 mg once daily or in 2 divided doses depending on formulation; increase as needed for heart rate control; usual effective dose: 360 mg/day (Ref).

Conversion between dosage forms:

Conversion from immediate-release to extended-release formulations: Patients stabilized on a maintenance regimen between 120 and 360 mg of immediate-release tablets may be switched to an extended-release formulation at the same daily dose administered in 1 or 2 divided doses depending on formulation. In some patients, the dosage of the extended-release formulation may require adjustment following conversion.

Conversion from IV infusion to oral: Immediate release can be started ~1 hour before stopping infusion. Oral daily dose may be estimated from the IV infusion rate by using the equation below. Round oral doses to the nearest appropriate strength and formulation.

Oral dose (mg per day) = [infusion rate (mg/hour) × 3 + 3] × 10

5 mg/hour = 180 mg/day.

10 mg/hour = 300 to 360 mg/day.

15 mg/hour = 480 mg/day.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Mild to severe impairment: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Not significantly dialyzed: No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Not significantly dialyzed: No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; extensively metabolized by the liver; half-life is increased in patients with cirrhosis.

Dosing: Older Adult

Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 120 mg once daily using extended-release capsule) and titrate to response (Ref).

Dosing: Pediatric

(For additional information see "Diltiazem: Pediatric drug information")

Atrial tachyarrhythmias, rate control

Atrial tachyarrhythmias, rate control (bridge to therapy): Very limited data available: Infants ≥6 months, Children, and Adolescents: IV: Initial bolus: 0.25 mg/kg over 5 minutes (maximum dose: 20 mg/dose [average adult dose]) followed by a continuous IV infusion; reported rate range in one study was 0.05 to 0.15 mg/kg/hour. Note: Usual adult infusion rate for arrhythmia is 5 to 15 mg/hour. Dose should be individualized based on patient response. Dosing based on a small study of 10 patients with atrial tachycardia (age range: 6 months to 21 years; most patients were adolescents) who received an initial bolus of 0.25 mg/kg/dose followed by a continuous infusion titrated to effect, reported effective range was 0.05 to 0.15 mg/kg/hour (mean infusion rate: 0.11 mg/kg/hour). Rate control was achieved in 9 of the 10 patients within 10 minutes of dosing. One patient required an additional bolus of 0.25 mg/kg. Median ventricular rate of study group prior to initial bolus was 275 ± 50 beats per minute (BPM) (range: 185 to 500 BPM), which decreased to a median of 166 BPM prior to initiation of continuous infusion and decreased to a median of 123 BPM after 10 minutes of continuous infusion; blood pressure was not significantly affected by diltiazem; qualitative systolic function did not worsen in the seven patients studied (Ref). Note: In adult patients, infusions >24 hours are not recommended; with administration of diltiazem infusion >24 hours, the possibility of decreased diltiazem clearance, prolonged elimination half-life, and increased diltiazem and/or diltiazem metabolite plasma concentrations should be considered. In trial of 10 pediatric patients, the median duration was 45 hours (mean: 54 hours; range: 14 to 126 hours) (Ref).

Hypertension

Hypertension: Limited data available:

Infants and Children: Oral: Immediate-release formulations: Initial: 1.5 to 2 mg/kg/day in 3 to 4 divided doses (Ref); increase gradually, at 1- to 2-day intervals until optimum response is obtained; usual maximum daily dose: 3.5 mg/kg/day (Ref); some experts recommend a higher maximum daily dose of 6 mg/kg/day up to 360 mg/day; whichever is less (Ref). Note: Once patient is established on a total daily dose, may convert to an extended release dosage form at the appropriate interval (once or twice daily) in children able to swallow capsules whole and receiving adequate mg amount (Ref).

Adolescents (Ref): Oral:

Immediate-release formulations: 30 to 120 mg/dose administered 3 to 4 times daily; usual daily dosage range: 180 to 360 mg/day

Extended-release formulations:

Capsule, extended release (once daily dosing; eg, Cardizem CD, Tiazac): 120 to 300 mg once daily

Capsule, extended release (twice daily dosing; eg, Cardizem SR): 120 to 300 mg/day in 2 divided doses

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustment provided in the manufacturer’s labeling; use with caution; extensively metabolized by the liver; half-life is increased in patients with cirrhosis.

Adverse Reactions (Significant): Considerations
Bradyarrhythmias

Diltiazem may cause first-degree atrioventricular (AV) block, second-degree atrioventricular block, complete atrioventricular block, or sinus bradycardia (Ref). Although reversal is possible after discontinuation, some patients continue to have symptoms (Ref). In patients whose symptoms resolve after discontinuation, permanent pacemaker (PPM) therapy will likely not be necessary; however, cases with recurrent or unresolved symptoms after discontinuation may warrant PPM placement (Ref).

Mechanism: Related to the pharmacologic action; inhibits L-type calcium channels, leading to prolonged refractoriness and slowing of AV nodal conduction (Ref).

Onset: Varied; may occur at any time during therapy (Ref).

Risk factors:

Concurrent use of other AV nodal-blocking agents (eg, beta-blockers) (Ref)

Older adults (Ref)

Chronic kidney disease (Ref)

Underlying AV node dysfunction (Ref)

Cutaneous hypersensitivity reactions

Diltiazem may cause cutaneous hypersensitivity reactions. Maculopapular rash is the most common cutaneous adverse reaction reported (Ref). Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis (AGEP) have occurred rarely (Ref). In general, improvement is observed 1 to 2 weeks after discontinuation (Ref). Other cutaneous reactions associated with diltiazem include subacute cutaneous lupus erythematosus, erythema multiforme, erythroderma, exfoliative dermatitis, and hypersensitivity angiitis (Ref). In comparison to other calcium channel blockers, diltiazem has been associated with more reports of cutaneous reactions (Ref).

Skin hyperpigmentation, often in a photodistributed pattern, has also been associated with diltiazem; may present as reticulated, brown, slate-gray, or gray-blue macules or patches most commonly on the face, neck, forearms, and chest (Ref). Gradual improvement is observed after discontinuation (Ref).

Mechanism: Delayed hypersensitivity reactions (including SCARs): Non–dose-related; immunologic. Type IV immune-mediated (T-cell mediated) hypersensitivity reactions (Ref). Skin hyperpigmentation: Not clearly established (Ref).

Onset: Varied; maculopapular rashes usually occur within 10 days after initiation (Ref). SCARs usually occur between 1 to 8 weeks of treatment (Ref); although, some cases of SJS/TEN may have a more rapid onset (Ref). AGEP usually occurs 1 to 2 weeks after initiation (Ref). Reports of skin hyperpigmentation range from 3 weeks to 12.5 years (Ref).

Risk factors:

Prior hypersensitivity reaction to diltiazem. Note: Cross-reactivity between diltiazem and other calcium channel blockers is not well defined. There are limited case reports of cross-reactivity (Ref), but these are inconsistent and may not be distinct reactions (Ref).

Skin hyperpigmentation:

- Extended-release formulations (Ref)

- Patients with Fitzpatrick phototype V and VI skin (Ref)

- Females (Ref)

- Older adults (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences represent ranges for various dosage forms. Patients with impaired ventricular function and/or conduction abnormalities may have higher incidence of adverse reactions.

>10%: Cardiovascular: Peripheral edema (5% to 15%; dose-related)

1% to 10%:

Cardiovascular: Bradycardia (3% to 4%), bundle branch block (<2%), cardiac arrhythmia (1%), complete atrioventricular block (<2%), ECG abnormality (<2%), edema (2% to 3%), extrasystoles (2%), first-degree atrioventricular block (3% to 4%), heart failure (<2%), hypotension (3% to 4%), lower extremity edema (5% to 8%), palpitations (1% to 2%), second-degree atrioventricular block (<2%), syncope (<2%), vasodilation (2% to 3%)

Dermatologic: Pruritus (<2%), skin photosensitivity (<2%) (Ramirez 2007), skin rash (1% to 2%) (Tuchinda 2014) (table 1)

Diltiazem: Adverse Reaction: Skin Rash

Drug (Diltiazem)

Placebo

Dose

Number of Patients (Diltiazem)

Number of Patients (Placebo)

2%

0%

540 mg

49

50

1%

0%

Up to 360 mg

158

50

Endocrine & metabolic: Albuminuria (<2%), gynecomastia (<2%), hyperglycemia (<2%), hyperuricemia (<2%), increased lactate dehydrogenase (<2%), increased thirst (<2%), weight gain (<2%)

Gastrointestinal: Abdominal swelling (2%), anorexia (<2%), constipation (<2%), diarrhea (1% to 2%), dysgeusia (<2%), dyspepsia (1% to 6%), nausea (2%), vomiting (<2%), xerostomia (<2%)

Genitourinary: Crystalluria (<2%), erectile dysfunction (2%), nocturia (<2%), polyuria (<2%), sexual difficulty (<2%)

Hematologic & oncologic: Petechia (<2%)

Hepatic: Increased serum alanine aminotransferase (<2%), increased serum alkaline phosphatase (<2%), increased serum aspartate transaminase (<2%)

Hypersensitivity: Hypersensitivity reaction (<2%)

Infection: Infection (1% to 6%)

Local: Burning sensation at injection site (≤4%), injection-site pruritus (≤4%)

Nervous system: Abnormal dreams (<2%), abnormal gait (<2%), amnesia (<2%), asthenia (1% to 4%), depression (<2%), dizziness (2% to 10%), drowsiness (<2%), fatigue (5%), hallucination (<2%), headache (2% to 8%), insomnia (<2%), nervousness (2%), pain (6%), paresthesia (<2%), personality changes (<2%), tremor (<2%)

Neuromuscular & skeletal: Gout (1% to 2%), increased creatine phosphokinase in blood specimen (<2%), muscle cramps (<2%), myalgia (2%), neck stiffness (<2%), osteoarthritis (<2%)

Ophthalmic: Amblyopia (<2%), conjunctivitis (2%), eye irritation (<2%)

Otic: Tinnitus (<2%)

Respiratory: Bronchitis (1% to 4%), cough (1% to 2%), dyspnea (1% to 6%), epistaxis (<2%), flu-like symptoms (2%), paranasal sinus congestion (1% to 2%), pharyngitis (6%), rhinitis (<2%)

<1%:

Cardiovascular: Atrial flutter, sinus node dysfunction, ventricular fibrillation, ventricular tachycardia

Dermatologic: Urticaria

Frequency not defined: Hepatic: Hepatic injury (Deng 2013; Shallcross 1987), increased serum bilirubin

Postmarketing:

Cardiovascular: Asystole (Moser 1996; Subahi 2018)

Dermatologic: Acute generalized exanthematous pustulosis (Gesierich 2006; Knowles 1998; Sáenz de Santa María García 2016; Vicente-Calleja 1997), alopecia, cutaneous lupus erythematosus (Crowson 1995; Srivastava 2003), erythema multiforme (Stern 1989; Wittal 1992), exfoliative dermatitis (Odeh 1997; Sousa-Basto 1993), maculopapular rash (Cholez 2003; Gonzalo Garijo 2005), psoriasis (Song 2021), skin hyperpigmentation (Siegel 2020), Stevens-Johnson syndrome (Sanders 1993; Taylor 1990), toxic epidermal necrolysis

Gastrointestinal: Gingival hyperplasia (Bowman 1988; Steele 1994)

Hematologic & oncologic: Hemolytic anemia, leukopenia, prolonged bleeding time, purpuric disease (Inui 2001), thrombocytopenia (Michalets 1997)

Hypersensitivity: Angioedema, hypersensitivity angiitis (Sheehan-Dare 1988)

Nervous system: Extrapyramidal reaction

Neuromuscular & skeletal: Myopathy (Ahmad 1993)

Ophthalmic: Periorbital edema (Friedland 1993), retinopathy

Contraindications

Oral: Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); hypotension (systolic <90 mm Hg); acute MI and pulmonary congestion

Intravenous (IV): Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); severe hypotension; cardiogenic shock; administration concomitantly or within a few hours of the administration of IV beta-blockers; atrial fibrillation or flutter associated with accessory bypass tract (eg, Wolff-Parkinson-White syndrome, short PR syndrome); ventricular tachycardia (with wide-complex tachycardia [QRS ≥0.12 seconds], must determine whether origin is supraventricular or ventricular)

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Pregnancy; use in women of childbearing potential; breastfeeding; concurrent use with IV dantrolene, ivabradine, or lomitapide; severe bradycardia (<40 beats per minute).

Warnings/Precautions

Concerns related to adverse effects:

• Hepatic effects: Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed and frequently resolve spontaneously. Significant elevations in hepatic transaminases (eg, alkaline phosphatase, LDH, AST, ALT) and signs of acute hepatic injury have also been observed 1 to 8 weeks after therapy initiation and have been reversible upon discontinuation.

• Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.

Disease-related concerns:

• Accessory bypass tract (eg, Wolff-Parkinson-White [WPW] syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract or preexcitation syndrome, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients (ACLS [Neumar 2010]; ACC/AHA [Joglar 2024]).

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Left ventricular dysfunction: Use with caution in left ventricular dysfunction; due to negative inotropic effects, may exacerbate condition. Avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (AHA/ACC/HFSA [Heidenreich 2022]).

• Renal impairment: Use with caution in patients with renal impairment.

Other warnings/precautions:

• Appropriate use: IV: Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of IV diltiazem. Use with caution in patients hemodynamically compromised; continuously monitor ECG and blood pressure during administration (especially during continuous IV infusion). Initial use should be, if possible, in a setting where monitoring and resuscitation equipment, including DC cardioversion/defibrillation, are present.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule Extended Release 12 Hour, Oral, as hydrochloride:

Generic: 60 mg, 90 mg, 120 mg

Capsule Extended Release 24 Hour, Oral, as hydrochloride:

Cardizem CD: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg [contains fd&c blue #1 (brilliant blue)]

Cartia XT: 120 mg, 180 mg, 240 mg

Cartia XT: 300 mg [contains fd&c blue #1 (brill blue) aluminum lake, fd&c blue #1 (brilliant blue), fd&c blue #2 (indigo carm) aluminum lake, fd&c red #40 (allura red ac dye), fd&c red #40(allura red ac)aluminum lake, quinoline (d&c yellow #10) aluminum lake, quinoline yellow (d&c yellow #10)]

Dilt-XR: 120 mg, 180 mg, 240 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye), quinoline yellow (d&c yellow #10)]

Taztia XT: 120 mg [contains corn starch, fd&c blue #1 (brill blue) aluminum lake, fd&c blue #1 (brilliant blue), fd&c blue #2 (indigo carm) aluminum lake, fd&c red #40 (allura red ac dye), fd&c red #40(allura red ac)aluminum lake, quinoline (d&c yellow #10) aluminum lake]

Taztia XT: 180 mg [contains corn starch, fd&c blue #1 (brill blue) aluminum lake, fd&c blue #1 (brilliant blue), fd&c blue #2 (indigo carm) aluminum lake, fd&c red #40(allura red ac)aluminum lake, fd&c yellow #6 (sunset yellow), quinoline (d&c yellow #10) aluminum lake, quinoline yellow (d&c yellow #10)]

Taztia XT: 240 mg [contains corn starch, fd&c blue #1 (brill blue) aluminum lake, fd&c blue #1 (brilliant blue), fd&c blue #2 (indigo carm) aluminum lake, fd&c red #40 (allura red ac dye), fd&c red #40(allura red ac)aluminum lake, quinoline (d&c yellow #10) aluminum lake]

Taztia XT: 300 mg [contains corn starch, fd&c blue #1 (brill blue) aluminum lake, fd&c blue #1 (brilliant blue), fd&c blue #2 (indigo carm) aluminum lake, fd&c red #40 (allura red ac dye), fd&c red #40(allura red ac)aluminum lake, fd&c yellow #6 (sunset yellow), quinoline (d&c yellow #10) aluminum lake, quinoline yellow (d&c yellow #10)]

Taztia XT: 360 mg [contains corn starch, fd&c blue #1 (brill blue) aluminum lake, fd&c blue #1 (brilliant blue), fd&c blue #2 (indigo carm) aluminum lake, fd&c red #40(allura red ac)aluminum lake, quinoline (d&c yellow #10) aluminum lake]

Tiadylt ER: 120 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]

Tiadylt ER: 180 mg [contains fd&c blue #1 (brilliant blue)]

Tiadylt ER: 240 mg, 300 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]

Tiadylt ER: 360 mg [contains fd&c blue #1 (brilliant blue)]

Tiadylt ER: 420 mg

Tiazac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]

Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg

Solution, Intravenous, as hydrochloride:

Generic: 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL); 125 mg/25 mL (25 mL)

Solution, Intravenous, as hydrochloride [preservative free]:

Generic: 25 mg/5 mL (5 mL [DSC]); 50 mg/10 mL (10 mL [DSC]); 125 mg/25 mL (25 mL [DSC])

Solution Reconstituted, Intravenous, as hydrochloride:

Generic: 100 mg (1 ea)

Tablet, Oral, as hydrochloride:

Cardizem: 30 mg [contains fd&c blue #1 (brill blue) aluminum lake, quinoline (d&c yellow #10) aluminum lake]

Cardizem: 60 mg [scored; contains fd&c blue #1 (brill blue) aluminum lake, fd&c yellow #6(sunset yellow)alumin lake, methylparaben, quinoline (d&c yellow #10) aluminum lake]

Cardizem: 120 mg [scored; contains fd&c yellow #6(sunset yellow)alumin lake, methylparaben, quinoline (d&c yellow #10) aluminum lake]

Generic: 30 mg, 60 mg, 90 mg, 120 mg

Tablet Extended Release 24 Hour, Oral, as hydrochloride:

Cardizem LA: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg

Matzim LA: 180 mg, 240 mg, 300 mg, 360 mg, 420 mg

Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsule ER 24 Hour Therapy Pack (Cardizem CD Oral)

120 mg (per each): $34.14

180 mg (per each): $43.07

240 mg (per each): $58.39

300 mg (per each): $76.48

360 mg (per each): $111.59

Capsule ER 24 Hour Therapy Pack (Cartia XT Oral)

120 mg (per each): $1.20

180 mg (per each): $1.45

240 mg (per each): $2.05

300 mg (per each): $2.66

Capsule ER 24 Hour Therapy Pack (dilTIAZem HCl ER Beads Oral)

120 mg (per each): $0.75 - $1.04

180 mg (per each): $0.90 - $1.25

240 mg (per each): $1.96

300 mg (per each): $2.54

360 mg (per each): $2.59

420 mg (per each): $1.77 - $2.85

Capsule ER 24 Hour Therapy Pack (dilTIAZem HCl ER Coated Beads Oral)

120 mg (per each): $0.91 - $1.20

180 mg (per each): $1.02 - $1.45

240 mg (per each): $1.40 - $2.05

300 mg (per each): $1.90 - $2.66

360 mg (per each): $9.17 - $10.23

Capsule ER 24 Hour Therapy Pack (dilTIAZem HCl ER Oral)

120 mg (per each): $1.14

180 mg (per each): $1.34

240 mg (per each): $1.43

Capsule ER 24 Hour Therapy Pack (Taztia XT Oral)

120 mg (per each): $1.14

180 mg (per each): $1.38

240 mg (per each): $1.96

300 mg (per each): $2.54

360 mg (per each): $2.59

Capsule ER 24 Hour Therapy Pack (Tiadylt ER Oral)

120 mg (per each): $1.04

180 mg (per each): $1.25

240 mg (per each): $1.78

300 mg (per each): $2.30

360 mg (per each): $2.34

420 mg (per each): $2.46

Capsule ER 24 Hour Therapy Pack (Tiazac Oral)

120 mg (per each): $2.36

180 mg (per each): $2.85

240 mg (per each): $4.05

300 mg (per each): $5.24

360 mg (per each): $5.34

420 mg (per each): $5.60

Capsule, 12-hour (dilTIAZem HCl ER Oral)

60 mg (per each): $3.17 - $3.97

90 mg (per each): $3.62 - $4.67

120 mg (per each): $4.73 - $6.52

Solution (dilTIAZem HCl Intravenous)

25 mg/5 mL (per mL): $0.52 - $0.91

50 mg/10 mL (per mL): $0.48 - $0.83

125 mg/25 mL (per mL): $0.28 - $0.53

Solution (reconstituted) (dilTIAZem HCl Intravenous)

100 mg (per each): $13.69

Tablet, 24-hour (Cardizem LA Oral)

120 mg (per each): $4.56

180 mg (per each): $4.82

240 mg (per each): $5.41

300 mg (per each): $7.03

360 mg (per each): $7.56

420 mg (per each): $8.19

Tablet, 24-hour (dilTIAZem HCl ER Oral)

120 mg (per each): $2.82 - $4.10

180 mg (per each): $2.86 - $2.98

240 mg (per each): $3.20 - $3.34

300 mg (per each): $4.16 - $4.34

360 mg (per each): $4.48 - $4.67

420 mg (per each): $4.85 - $5.06

Tablet, 24-hour (Matzim LA Oral)

180 mg (per each): $2.98

240 mg (per each): $3.34

300 mg (per each): $4.34

360 mg (per each): $4.67

420 mg (per each): $5.06

Tablets (Cardizem Oral)

30 mg (per each): $7.68

60 mg (per each): $12.05

120 mg (per each): $22.18

Tablets (dilTIAZem HCl Oral)

30 mg (per each): $1.00

60 mg (per each): $1.57

90 mg (per each): $2.14

120 mg (per each): $2.88

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule Extended Release 24 Hour, Oral, as hydrochloride:

Cardizem CD: 120 mg [DSC], 180 mg [DSC], 240 mg [DSC], 300 mg [DSC]

Tiazac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg [contains fd&c blue #1 (brilliant blue), fd&c red #40 (allura red ac dye)]

Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg

Solution, Intravenous:

Generic: 5 mg/mL (5 mL, 10 mL)

Tablet, Oral, as hydrochloride:

Generic: 30 mg, 60 mg

Tablet Extended Release 24 Hour, Oral, as hydrochloride:

Tiazac XC: 120 mg, 360 mg, 180 mg/24 hr, 240 mg/24 hr, 300 mg/24 hr

Generic: 180 mg, 240 mg, 300 mg, 360 mg

Administration: Adult

Oral:

IR tablet (eg, Cardizem): Administer before meals and at bedtime. Tablets may be swallowed whole, crushed, or chewed; do not split nonscored tablets.

Long-acting dosage forms: Do not open, chew, or crush; swallow whole. Administer at same time of day either morning or evening.

Cardizem CD, Cardizem LA, Cartia XT, Matzim LA: Administer without regard to meals.

Dilt-XR: Administer on an empty stomach in the morning.

Taztia XT, Tiazac: Capsules may be opened and sprinkled on a spoonful of applesauce. Applesauce should not be hot and should be swallowed without chewing, followed by drinking a glass of water.

Tiazac XC [Canadian product]: Administer at bedtime.

Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Tiazac or generic equivalent capsule may be opened and contents sprinkled onto soft food of choice. Other ER formulations, such as Cardizem CD, LA, SR or generic equivalents have no data on opening capsule. Dilacor XR or generic equivalent manufacturers say do not open capsule.

IV: Bolus doses given over 2 minutes with continuous ECG and blood pressure monitoring. Continuous infusion should be via infusion pump. May increase infusion rate in 5 mg/hour increments as needed (maximum: 15 mg/hour). Response to bolus may require several minutes to reach maximum. Response may persist for several hours after infusion is discontinued.

Administration: Pediatric

Oral:

Tablet, immediate release (eg, Cardizem): Administer before meals and at bedtime. Tablets may be swallowed whole, crushed, or chewed; scored tablets may be split.

Extended-release preparations: Swallow whole; do not chew, break, or crush. Administer at the same time of day, either morning or evening.

Cardizem CD, Cardizem LA, Cartia XT, Matzim LA: May be administered with or without food, but should be administered consistently with relation to meals; administer with a full glass of water.

Taztia XT and Tiazac: Capsules may be opened and sprinkled on applesauce; swallow applesauce immediately, do not chew; follow with some cool water (adults: 1 glass) to ensure complete swallowing; do not use hot applesauce; do not divide capsule contents (ie, do not administer partial doses); do not store mixture of applesauce and capsule contents, use immediately.

Parenteral:

IV bolus: Pediatric patients ≥6 months of age: Administration over 5 minutes at a concentration ≤5 mg/mL with continuous ECG monitoring has been used (Ref).

Continuous IV infusion: Administer as a continuous IV infusion with the use of an infusion pump with continuous ECG monitoring. Response may persist for several hours after infusion is discontinued.

Usual Infusion Concentrations: Adult

IV infusion: 125 mg in 125 mL (total volume) (concentration: 1 mg/mL) of D5W or NS

Use: Labeled Indications

Oral: Hypertension, chronic stable angina, vasospastic angina

Injection: Atrial fibrillation or atrial flutter for acute ventricular rate control, conversion of supraventricular tachycardia

Use: Off-Label: Adult

Atrial fibrillation or atrial flutter, chronic ventricular rate control; Chest pain associated with cocaine ingestion, with or without evidence of acute coronary syndrome; Hypertrophic cardiomyopathy; Idiopathic ventricular tachycardia; Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic; Pulmonary arterial hypertension, group 1; Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifocal atrial tachycardia)

Medication Safety Issues
Sound-alike/look-alike issues:

Cardizem may be confused with Cardene, Cardene SR, Cardizem CD, Cardizem SR, cortisone

Cartia XT may be confused with Procardia XL

DilTIAZem may be confused with Calan, diazePAM, Dilantin

Tiazac may be confused with Tigan, Tiazac XC [CAN], Ziac

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (antiarrhythmic agent, IV) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care Settings).

Older Adult: High-Risk Medication:

Diltiazem is identified in the Screening Tool of Older Person's Prescriptions (STOPP) criteria as a potentially inappropriate medication in older adults (≥65 years of age). Some disease states of concern include heart failure, bradycardia, heart block (type II or complete), and severe symptomatic aortic stenosis (O’Mahony 2023).

Administration issues:

Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.

International issues:

Cardizem [US, Canada, and multiple international markets] may be confused with Cardem brand name for celiprolol [Spain]

Cartia XT [US] may be confused with Cartia brand name for aspirin [multiple international markets]

DilacorXR [New Zealand, Puerto Rico] may be confused with Pilocar brand name for Pilocarpine, Ophthalmic [multiple international markets]

Dipen [Greece] may be confused with Depen brand name for penicillamine [US]; Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]

Tiazac: Brand name for dilTIAZem [US, Canada], but also the brand name for pioglitazone [Chile]

Metabolism/Transport Effects

Substrate of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2D6 (weak), CYP3A4 (moderate)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary. Risk C: Monitor therapy

Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib. Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use. Risk D: Consider therapy modification

ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil. Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined. Risk D: Consider therapy modification

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. Risk C: Monitor therapy

Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). Risk C: Monitor therapy

ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam. Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy). Risk D: Consider therapy modification

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider therapy modification

Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported. Risk C: Monitor therapy

AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. Risk C: Monitor therapy

Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. Risk C: Monitor therapy

Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. Risk X: Avoid combination

Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations. Risk C: Monitor therapy

ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. Risk C: Monitor therapy

Aspirin: Calcium Channel Blockers (Nondihydropyridine) may enhance the antiplatelet effect of Aspirin. Risk C: Monitor therapy

Astemizole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Astemizole. Management: Avoid concomitant use of astemizole and moderate CYP3A4 inhibitors whenever possible. If combined, monitor closely for increased astemizole toxicities, especially for QTc interval prolongation. Risk D: Consider therapy modification

Atazanavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atazanavir. Risk C: Monitor therapy

Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. Risk C: Monitor therapy

Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. Risk C: Monitor therapy

Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor therapy

Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. Risk C: Monitor therapy

Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil. Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism). Risk D: Consider therapy modification

Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib. Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis. Risk D: Consider therapy modification

Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. Risk C: Monitor therapy

Bedaquiline: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bedaquiline. Risk C: Monitor therapy

Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. Risk C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. Risk C: Monitor therapy

Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. Risk C: Monitor therapy

Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. Risk C: Monitor therapy

Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. Risk X: Avoid combination

Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents. Risk C: Monitor therapy

Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole. Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer. Risk C: Monitor therapy

Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib. Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg). Risk D: Consider therapy modification

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine. Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations. Risk D: Consider therapy modification

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk X: Avoid combination

Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). Risk C: Monitor therapy

Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess. Risk D: Consider therapy modification

Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). Risk X: Avoid combination

Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. Risk C: Monitor therapy

BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. Risk C: Monitor therapy

Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. Risk C: Monitor therapy

Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers. Risk C: Monitor therapy

Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. Risk C: Monitor therapy

Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib. Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions. Risk D: Consider therapy modification

CarBAMazepine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine concentrations and toxicities and monitor for decreased calcium channel blocker efficacy. Risk D: Consider therapy modification

Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides. Risk C: Monitor therapy

Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. Risk C: Monitor therapy

Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Risk D: Consider therapy modification

Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol. Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors. Risk D: Consider therapy modification

Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Risk C: Monitor therapy

Cisapride: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cisapride. Management: Consider alternatives to this combination. Prescribing information for some moderate CYP3A4 inhibitors state coadministration with cisapride is contraindicated, while some others recommend monitoring and dose titration. Risk D: Consider therapy modification

Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. Risk C: Monitor therapy

CloZAPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. Risk C: Monitor therapy

Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib. Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses. Risk D: Consider therapy modification

Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. Risk C: Monitor therapy

Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine. Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details. Risk D: Consider therapy modification

Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. Risk C: Monitor therapy

Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. Risk C: Monitor therapy

Crizotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Crizotinib. Risk C: Monitor therapy

CycloSPORINE (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Risk C: Monitor therapy

CYP3A4 Inducers (Moderate): May decrease the serum concentration of DilTIAZem. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of DilTIAZem. Management: Consider alternatives to this combination when possible. If combined, monitor for decreased diltiazem efficacy. Risk D: Consider therapy modification

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DilTIAZem. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of DilTIAZem. Risk C: Monitor therapy

Dabrafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. Risk C: Monitor therapy

Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers. Risk X: Avoid combination

Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine. Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4. Risk D: Consider therapy modification

Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant. Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors. Risk D: Consider therapy modification

Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. Risk C: Monitor therapy

Dasatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dasatinib. Risk C: Monitor therapy

Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort. Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor. Risk D: Consider therapy modification

Delamanid: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Delamanid. Risk C: Monitor therapy

DexAMETHasone (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DexAMETHasone (Systemic). Risk C: Monitor therapy

Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. Risk C: Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. Risk C: Monitor therapy

Disopyramide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Disopyramide. Risk C: Monitor therapy

DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. Risk C: Monitor therapy

Dofetilide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. Risk C: Monitor therapy

Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. Risk X: Avoid combination

DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). Risk X: Avoid combination

DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. Risk C: Monitor therapy

Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Management: Use lower starting doses of the nondihydropyridine calcium channel blockers and only increase calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated. Monitor closely during coadministration. Risk D: Consider therapy modification

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. Risk C: Monitor therapy

Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. Risk X: Avoid combination

Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. Risk C: Monitor therapy

Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. Risk X: Avoid combination

Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days. Risk D: Consider therapy modification

Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat. Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated. Risk D: Consider therapy modification

Encorafenib: DilTIAZem may increase the serum concentration of Encorafenib. Encorafenib may decrease the serum concentration of DilTIAZem. Management: Avoid use of encorafenib and diltiazem when possible. If combined, decrease the encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Monitor for reduced diltiazem efficacy. Risk D: Consider therapy modification

Entrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Entrectinib. Management: Avoid moderate CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg/day if starting dose 200 mg; to 100 mg/day if starting dose 300 mg; to 200 mg if starting dose 400 mg or 600 mg. Risk D: Consider therapy modification

Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone. Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily. Risk D: Consider therapy modification

Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). Risk C: Monitor therapy

Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. Risk C: Monitor therapy

Erythromycin (Systemic): May increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Erythromycin (Systemic). Risk C: Monitor therapy

Esmolol: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Esmolol. Management: Administration of IV verapamil or diltiazem together with esmolol is contraindicated if one agent is given while the effects of the other are still present. Canadian esmolol labeling specifies that use within 24 hours is contraindicated. Risk D: Consider therapy modification

Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. Risk C: Monitor therapy

Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. Risk C: Monitor therapy

Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus. Risk C: Monitor therapy

Fedratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fedratinib. Risk C: Monitor therapy

Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. Risk C: Monitor therapy

FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL. Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal. Risk D: Consider therapy modification

Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. Risk X: Avoid combination

Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. Risk C: Monitor therapy

Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod. Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose. Risk D: Consider therapy modification

Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin. Risk X: Avoid combination

Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). Risk C: Monitor therapy

Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). Risk C: Monitor therapy

Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. Risk C: Monitor therapy

Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. Risk X: Avoid combination

Fosphenytoin-Phenytoin: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Management: Consider alternatives to this combination when possible. If combined, monitor for increased phenytoin concentrations and toxicities and monitor for decreased calcium channel blocker efficacy. Risk D: Consider therapy modification

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider therapy modification

Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone. Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use. Risk D: Consider therapy modification

Gilteritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gilteritinib. Risk C: Monitor therapy

Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. Risk C: Monitor therapy

GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE. Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined. Risk D: Consider therapy modification

Guggul: May decrease the serum concentration of DilTIAZem. Risk C: Monitor therapy

Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine. Risk C: Monitor therapy

Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions. Risk D: Consider therapy modification

Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. Risk C: Monitor therapy

Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. Risk C: Monitor therapy

Iloperidone: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Indoramin: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. Risk X: Avoid combination

Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers. Risk C: Monitor therapy

Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. Risk C: Monitor therapy

Isavuconazonium Sulfate: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations. Risk C: Monitor therapy

Isocarboxazid: May enhance the antihypertensive effect of Antihypertensive Agents. Risk X: Avoid combination

Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. Risk C: Monitor therapy

Itraconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Itraconazole. Risk C: Monitor therapy

Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. Risk X: Avoid combination

Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor. Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations. Risk D: Consider therapy modification

Ivosidenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivosidenib. Management: Avoid use of moderate CYP3A4 inhibitors with ivosidenib whenever possible. If combined, monitor for increased ivosidenib toxicities, including QTc prolongation. Risk D: Consider therapy modification

Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. Risk C: Monitor therapy

Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. Risk C: Monitor therapy

Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. Risk C: Monitor therapy

Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. Risk C: Monitor therapy

Lefamulin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lefamulin. Management: Monitor for lefamulin adverse effects during coadministration of lefamulin tablets with moderate CYP3A4 inhibitors. Risk C: Monitor therapy

Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. Risk X: Avoid combination

Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. Risk C: Monitor therapy

Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. Risk C: Monitor therapy

Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. Risk C: Monitor therapy

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. Risk C: Monitor therapy

Levoketoconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levoketoconazole. Risk C: Monitor therapy

Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. Risk C: Monitor therapy

Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. Risk C: Monitor therapy

Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). Risk C: Monitor therapy

Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination. Risk C: Monitor therapy

Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. Risk X: Avoid combination

Lonafarnib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lonafarnib. Risk C: Monitor therapy

Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Lopinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lopinavir. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Lovastatin: DilTIAZem may increase the serum concentration of Lovastatin. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving diltiazem. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis). Risk D: Consider therapy modification

Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone. Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor. Risk D: Consider therapy modification

Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone. Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products. Risk D: Consider therapy modification

Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin. Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated. Risk D: Consider therapy modification

Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. Risk C: Monitor therapy

Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. Risk C: Monitor therapy

Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. Risk C: Monitor therapy

Mavacamten: Calcium Channel Blockers (Nondihydropyridine) may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Mavacamten. Management: Start mavacamten at 5 mg/day if stable on a non-DHP CCB. For those stable on mavacamten who are initiating a non-DHP CCB, reduce mavacamten dose by one dose level. Monitor for excessive negative inotropic effects. Risk D: Consider therapy modification

Mavorixafor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mavorixafor. Risk C: Monitor therapy

Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. Risk C: Monitor therapy

Methadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methadone. Management: If coadministration with moderate CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation. Risk D: Consider therapy modification

Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. Risk C: Monitor therapy

Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. Risk X: Avoid combination

Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam. Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined. Risk D: Consider therapy modification

Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Midostaurin: DilTIAZem may increase the serum concentration of Midostaurin. Management: Seek alternatives to the concomitant use of midostaurin and diltiazem if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions. Risk D: Consider therapy modification

MiFEPRIStone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MiFEPRIStone. Risk C: Monitor therapy

Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. Risk C: Monitor therapy

Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat. Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects. Risk D: Consider therapy modification

Mobocertinib: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mobocertinib. Management: Avoid use of moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely. Risk D: Consider therapy modification

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. Risk C: Monitor therapy

Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. Risk C: Monitor therapy

Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability). Risk D: Consider therapy modification

Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. Risk C: Monitor therapy

Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. Risk C: Monitor therapy

Nilotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nilotinib. Risk C: Monitor therapy

NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. Risk C: Monitor therapy

Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. Risk X: Avoid combination

Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. Risk X: Avoid combination

Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib. Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily. Risk D: Consider therapy modification

Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. Risk C: Monitor therapy

Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. Risk C: Monitor therapy

Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone. Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily. Risk D: Consider therapy modification

Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. Risk X: Avoid combination

OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. Risk C: Monitor therapy

Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). Risk C: Monitor therapy

PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). Risk C: Monitor therapy

Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. Risk X: Avoid combination

Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. Risk C: Monitor therapy

Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene. Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined. Risk D: Consider therapy modification

Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. Risk C: Monitor therapy

PAZOPanib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PAZOPanib. Risk C: Monitor therapy

Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib. Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed. Risk D: Consider therapy modification

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib. Management: If combined use cannot be avoided, pexidartinib dose should be reduced as follows: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily; reduce pexidartinib 250 mg daily to 125 mg once daily. Risk D: Consider therapy modification

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Risk C: Monitor therapy

Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. Risk C: Monitor therapy

Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. Risk C: Monitor therapy

Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. Risk X: Avoid combination

Piperaquine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Piperaquine. Risk C: Monitor therapy

Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. Risk C: Monitor therapy

PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. Risk C: Monitor therapy

Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod. Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm. Risk D: Consider therapy modification

Pralsetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pralsetinib. Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily. Risk D: Consider therapy modification

Pramipexole: DilTIAZem may enhance the hypotensive effect of Pramipexole. DilTIAZem may increase the serum concentration of Pramipexole. Risk C: Monitor therapy

Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. Risk C: Monitor therapy

Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. Risk C: Monitor therapy

Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

QUEtiapine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QUEtiapine. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

QuiNIDine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNIDine. Risk C: Monitor therapy

Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). Risk C: Monitor therapy

QuiNINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNINE. Risk C: Monitor therapy

Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine. Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use. Risk D: Consider therapy modification

Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased. Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis). Risk D: Consider therapy modification

Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. Risk C: Monitor therapy

Repotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Repotrectinib. Risk X: Avoid combination

Ribociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ribociclib. Risk C: Monitor therapy

Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. Risk C: Monitor therapy

Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant. Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine. Risk D: Consider therapy modification

Rivaroxaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein. For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations. Risk C: Monitor therapy

Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. Risk C: Monitor therapy

Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. Risk C: Monitor therapy

Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). Risk C: Monitor therapy

Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. Risk C: Monitor therapy

Saquinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saquinavir. Risk C: Monitor therapy

SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. Risk C: Monitor therapy

Selpercatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selpercatinib. Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 80 mg twice/day, or from 160 mg twice/day to 120 mg twice/day. Risk D: Consider therapy modification

Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib. Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information. Risk D: Consider therapy modification

Sertindole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sertindole. Risk X: Avoid combination

Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. Risk C: Monitor therapy

Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. Risk C: Monitor therapy

Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. Risk X: Avoid combination

Simvastatin: May decrease the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of Simvastatin. Management: Avoid concurrent use of diltiazem with simvastatin when possible. If used together, limit adult doses to simvastatin 10 mg daily and diltiazem 240 mg per day; monitor closely for signs of simvastatin toxicity (eg, myositis, rhabdomyolysis). Risk D: Consider therapy modification

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring. Risk D: Consider therapy modification

Sirolimus (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Conventional). Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required. Risk D: Consider therapy modification

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m2 when used concomitantly with a moderate CYP3A4 inhibitor. Risk D: Consider therapy modification

Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. Risk C: Monitor therapy

Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib. Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible. When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions). Risk D: Consider therapy modification

Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. Risk C: Monitor therapy

SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. Risk C: Monitor therapy

SUNItinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUNItinib. Risk C: Monitor therapy

Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy. Risk D: Consider therapy modification

Tacrolimus (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy

Tacrolimus (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Topical). Risk C: Monitor therapy

Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. Risk C: Monitor therapy

Talazoparib: DilTIAZem may increase the serum concentration of Talazoparib. Risk C: Monitor therapy

Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. Risk C: Monitor therapy

Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat. Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily. Risk D: Consider therapy modification

Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. Risk C: Monitor therapy

Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. Risk C: Monitor therapy

Terfenadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Terfenadine. Risk C: Monitor therapy

Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. Risk C: Monitor therapy

Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. Risk C: Monitor therapy

Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor. Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph Risk D: Consider therapy modification

Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine. Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication. Risk D: Consider therapy modification

Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. Risk C: Monitor therapy

Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. Risk C: Monitor therapy

Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C: Monitor therapy

Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. Risk C: Monitor therapy

Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. Risk C: Monitor therapy

Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM. Risk D: Consider therapy modification

Toremifene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Toremifene. Risk C: Monitor therapy

Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. Risk C: Monitor therapy

TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. Risk C: Monitor therapy

TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. Risk C: Monitor therapy

Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam. Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors. Risk D: Consider therapy modification

Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors. Risk D: Consider therapy modification

Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. Risk C: Monitor therapy

Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. Risk C: Monitor therapy

Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. Risk C: Monitor therapy

Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. Risk C: Monitor therapy

Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. Risk C: Monitor therapy

Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US. Risk D: Consider therapy modification

Vemurafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vemurafenib. Risk C: Monitor therapy

Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors. Risk D: Consider therapy modification

Verapamil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Verapamil. Risk C: Monitor therapy

Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. Risk C: Monitor therapy

VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. Risk C: Monitor therapy

VinCRIStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine. Risk C: Monitor therapy

VinCRIStine (Liposomal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine (Liposomal). Risk C: Monitor therapy

Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. Risk C: Monitor therapy

Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. Risk C: Monitor therapy

Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin. Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors. Risk D: Consider therapy modification

Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. Risk C: Monitor therapy

Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib. Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details. Risk D: Consider therapy modification

Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. Risk C: Monitor therapy

Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. Risk C: Monitor therapy

Food Interactions

Grapefruit juice may increase the serum concentration of diltiazem. Management: Monitor response to diltiazem with concurrent use.

Reproductive Considerations

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Diltiazem is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).

Pregnancy Considerations

Adverse events have been observed in animal reproduction studies.

Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).

Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is indicated, agents other than diltiazem may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).

Breastfeeding Considerations

Diltiazem is present in breast milk.

Data related to the presence of diltiazem in breast milk are available from a case report. Oral diltiazem 60 mg four times a day was started in a mother on postpartum day 14 for arrythmia. Four days later maternal blood and breast milk were sampled. Peak breast milk concentrations of diltiazem were 200 ng/mL, similar to those in the maternal serum. Breast milk concentrations decreased to <50 mg/mL 22 hours after the final diltiazem dose (Okada 1985).

Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother; however, other sources consider diltiazem compatible for use in patients who are breastfeeding (ESC [Cífková 2020]).

Monitoring Parameters

BP; heart rate; liver function.

Mechanism of Action

Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Oral: Immediate release tablet: 30 to 60 minutes; IV: Bolus: 3 minutes

Duration: IV: Bolus: 1 to 3 hours; Continuous infusion (after discontinuation): 0.5 to 10 hours

Absorption: Immediate release tablet: ~98%; Extended release capsule: ~93% to >95%

Distribution: Vd: 3 to 13 L/kg

Protein binding: 70% to 80%

Metabolism: Hepatic (extensive first-pass effect) via CYP-450 and conjugation; forms metabolites N-monodesmethyldiltiazem, desacetyldiltiazem, desacetyl-Nmonodesmethyldiltiazem, desacetyl-O-desmethyldiltiazem, and desacetyl-N, O-desmethyldiltiazem; following single IV injection, plasma concentrations of N-monodesmethyldiltiazem and desacetyldiltiazem are typically undetectable; however, these metabolites accumulate to detectable concentrations following 24-hour constant rate infusion.

Bioavailability: Oral: ~40% (undergoes extensive first-pass metabolism)

Half-life elimination: Immediate release tablet: 3 to 4.5 hours; Extended release tablet: 6 to 9 hours; Extended release capsules: 4 to 9.5 hours; IV: single dose: ~3.4 hours; continuous infusion: 4 to 5 hours

Time to peak, serum: Immediate release tablet: 2 to 4 hours; Extended release tablet: 11 to 18 hours; Extended release capsule: 10 to 14 hours

Excretion: Urine (2% to 4% as unchanged drug); feces

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Bioavailability is increased, and half-life is prolonged.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Adizem XL | Cardil | Dilzem | Mono-tildiem | Tildiem;
  • (AR) Argentina: Acalix | Acalix a.p. | Acalix cd | Acalix cronos | Dilauran | Diltenk | Diltenk ap 90 | Diltiazem fada | Diltiazem northia | Dilzen g | Hart | Hart a.p. | Hart cd | Incoril | Kaltiazem | Tilazem;
  • (AT) Austria: Corazem | Diltiastad | Diltiazem | Diltiazem genericon pharma | Dilzem | Dilzem rr;
  • (AU) Australia: Apo Diltiazem | Auscard | Cardizem | Cm diltiazem | Coras | Dbl diltiazem | Diltahexal | Diltiazem | Diltiazem actavis | Diltiazem an | Diltiazem bc | Diltiazem pfizer | Diltiazem sandoz | Dilzem | Dilzem cd | Sbpa diltiazem | Tw diltiazem | Vasocardol;
  • (BD) Bangladesh: Adil | Cardil | Cardizem | Delcard | Diazem | Dilazem | Dilcontin | Dilgem | Dilti | Diltizem | Evascon | Herbesser | Litizem | Neocard;
  • (BE) Belgium: Diltiazem eg | Diltiazem ratiopharm | Diltiazem sandoz | Diltiazem teva | Diltiazem teva generics belgium | Progor | Tildiem;
  • (BG) Bulgaria: Aldizem | Altiazem rr | Diacordin | Diltiazem | Diltizem | Dilzem;
  • (BR) Brazil: Angiolong | Angiolong ap | Balcor | Balcor e.v. | Calzem | Cardizem | Cloridrato de diltiazem | Cordil | Diltiacor | Diltipress | Diltizem | Diltor cd | Incoril;
  • (CH) Switzerland: Diltiazem mepha | Diltiazem skyepharma | Dilzem;
  • (CL) Chile: Acasmul | Cordis | Grifodilzem | Incoril | Tilazem | Tildiem;
  • (CN) China: Ai ke lang | Di heng | Diltiazem | Dilzem sr | Ergolan | Herbesser | Jian er xin | Mono-tildiem | Qin er kang | Tian er xin | Xintai;
  • (CO) Colombia: Angiotrofin | Angoral | Corazem cd | Diltiasyn | Diltiazem | Tilazem;
  • (CZ) Czech Republic: Blocalcin | Diacordin;
  • (DE) Germany: Corazet Diltiazem | Dil sanorania | Dilsal | Dilta | Diltabeta | Diltahexal | Diltapham | Diltaretard | Dilti | Diltia | Diltiagamma | Diltiamerck | Diltiazem | Diltiazem 1 A Pharm | Diltiazem ethypharm | Diltiazem Siga | Diltiazem stada | Diltiazem Temmler | Diltiazem Verla | Diltiuc | Dilzanton | Dilzem | Dilzicardin | Tilker;
  • (DK) Denmark: Myonil;
  • (DO) Dominican Republic: Altiazem | Angiotrofin | Cirilen | Cirilen CD | Diltiax | Diltiazem | Incoril | Lacerol | Lacerol HTA | Lufrazem | Rozen | Tilazem;
  • (EC) Ecuador: Arterodoxial | Cirilen | Diltiazem | Incoril | Incoril ap | Incoril monodosis | Tilazem;
  • (EE) Estonia: Altiazem rr | Cardil | Dilatam | Dilrene | Diltiazem | Diltisan | Dilzem;
  • (EG) Egypt: Altiazem | Angitect | Delay Tiazem | Diltacor XL | Diltiazem | Mono-tildiem | Peltiam | Telzim | Tildiem;
  • (ES) Spain: Angiodrox | Cardiser | Carreldon | Corolater | Cronodine | Dilaclan | Dilaclan hta | Diltiazem alter | Diltiazem bayvit | Diltiazem cinfa | Diltiazem edigen | Diltiazem esteve | Diltiazem mundogen | Diltiazem qualix | Diltiazem Ranbaxy | Diltiazem stada | Diltiwas | Diltiwas retard | Dinisor | Doclis | Lacerol | Lacerol cor | Masdil | Tilker | Trumsal | Uni masdil;
  • (FI) Finland: Cardizem | Dilmin | Dilpral | Diltical | Dilzem | Viazem;
  • (FR) France: Bi tildiem | Deltazen | Diacor | Dilrene | Diltiazem | Diltiazem arrow | Diltiazem bgr | Diltiazem biogaran | Diltiazem cristers | Diltiazem g gam | Diltiazem gnr | Diltiazem ivax | Diltiazem merck | Diltiazem msd | Diltiazem Panpharma | Diltiazem ratiopharm | Diltiazem rpg | Diltiazem sandoz | Diltiazem teva | Diltiazem teva sante | Diltiazem Zentiva | Diltiazem zentiva lab | Mono tildiem | Monotildiem | Tildiem;
  • (GB) United Kingdom: Adizem | Angiozem | Angitil | Bi carzem | Britiazim | Calazem | Calcicard | Calcicard 3m | Dilcardia | Diltiazem | Diltiazem arrow | Diltiazem berk | Diltiazem kent | Diltiazem sandoz | Diltiazem teva | Dilzem | Disogram | Horizem | Kenzem | Metazem | Optil | Retalzem | Slozem | Tiamex | Tildiem | Tildiem la | Viazem | Zemret | Zemtard | Zildil;
  • (GR) Greece: Alfener | Cardil | Corsenile | Diltelan | Dilzanol | Dipen | Elvesil | Ergoclavin | Mavitalon | Mycarzem | Natasadol | Rubiten | Saubasin | Ternel | Tildiem | Zilden;
  • (HK) Hong Kong: Apo diltiaz | Diazem | Dilatam | Dilem | Diltan | Diltiazem | Herbesser | Syn-diltiazem | Tildiem | Wontizem;
  • (HR) Croatia: Aldizem | Diltiazem Pliva;
  • (HU) Hungary: Blocalcin | Dilrene | Diltan-sr | Diltiazem b | Dilzem;
  • (ID) Indonesia: Carditen | Cardyne | Cordila | Cordizem | Dilbres | Dilmen | Dilso | Diltan | Diltiazem | Diltikor | Farmabes | Herbesser | Herbesser CD | Lanodil;
  • (IE) Ireland: Adizem | Diltam | Diltiazem | Dilzem | Dilzem sr | Entrydil | Tildiem | Zemtard;
  • (IL) Israel: Adizem CD | Dilatam | Levodex | Levozem;
  • (IN) India: Altiazem | Angizem | Cardem | Channel | Coriem-xl | Delwin | Dicard | Dilcal | Dilcardia | Dilcare | Dilcontin | Dilgard | Dilmax | Dilocor | Dilt | Diltanol | Diltara | Dilter | Dilti | Diltiaz | Diltilong | Diltime | Dilzem | Dilzem sr | Dilzor | Dtm | Dz | Dzm | Heartil | Icidil | Ionozem | Ionozem cd | Isdil | Iski | Kaizem | Lodil | Masdil | Onzem | Q-dil-cd | Sirdil | Tiacard;
  • (IQ) Iraq: AwaDilazim;
  • (IS) Iceland: Korzem | Korzem R;
  • (IT) Italy: Altiazem | Angipress | Angizem | Carzem | Citizem | Diacardin | Diladel | Dilem | Diliter | Diltiazem | Diltiazem doc | Diltiazem drm | Diltiazem eg | Diltiazem Mylan | Diltiazem San | Diltiazem sandoz | Dilzene | Dilzener | Etyzem | Longazem | Tildiem;
  • (JO) Jordan: Altiazem | Bi tildiem | Corzem | Dilzacard | Dilzem | Mono tildiem | Tildiem;
  • (JP) Japan: Calnurs | Clarute santen | Clarute sawai | Clarute yoshitomi | Coroherser nichiiko | Coroherser r | Diltiazem hcl isei | Diltiazem hcl ohara | Frotty | Gadoserin | Helsibon | Hemarekeat | Herbesser | Herbesser r | Herbesser r100 | Herbesser r200 | Hirosutas r | Lutianon r | Marumunen | Miocardie nissin | Nackless | Paretnamin | Paretnamin taisho | Pazeadin | Seresnatt | Sunlight | Tiaves hexal | Tiaves nichiiko | Yohtiazem | Yohtiazem mita | Yohtiazem nichiiko | Yohtiazem yoshindo | Youtiazem | Ziruvate choseido | Ziruvate kayaku | Ziruvate nisshin kyorin sei;
  • (KE) Kenya: Dilcontin xl | Mono tildiem sr;
  • (KR) Korea, Republic of: Cardiazem | Cardiben | Carzem | Deltazem | Diltam | Diltelan | Diltiazem | Diltren | Heartzem | Herben | Herben sr | Heripesa | Miozem | Tazem | Tiaben;
  • (KW) Kuwait: Bi tildiem | Diltan | Dilzem | Mono-tildiem | Tildiem;
  • (LB) Lebanon: Adizem XL | Altiazem | Apo diltiaz | Apo Diltiazem | Diltan | Diltiaretard | Diltiaz | Diltiazem | Dilzem | Tildiem | Zaldem;
  • (LT) Lithuania: Altiazem rr | Apo Diltiazem | Blocalcin | Cardil | Diacordin | Diazem | Dilrene | Diltiazem | Diltisan | Diltizem | Dilzem;
  • (LU) Luxembourg: Diltahexal | Diltiazem eg | Diltiazem sandoz | Progor | Tildiem;
  • (LV) Latvia: Aldizem | Altiazem rr | Blocalcin | Cardil | Diacordin | Dilatan | Dilrene | Dilteks | Diltiazem | Diltiazem ratiopharm | Diltisan | Diltizem | Dilzem;
  • (MA) Morocco: Adizem | Altiazem | Bi tildiem | Cronodine | Dilrene | Mono tildiem | Progor | Retalzem | Tildiem;
  • (MX) Mexico: Angiotrofin | Angiotrofin a.p. | Angiotrofin retard | Anremed | Dasav | Diltiazem g.i. | Sertidel | Tilazem;
  • (MY) Malaysia: Apo Diltiazem | Calcizem | Cardil | Cascor XL | Diazem | Dilcard | Dilem | Diltizem | Herbesser | Mono-tildiem | Tildiem;
  • (NL) Netherlands: Diloc | Diltiazem HCL | Diltiazem hcl a | Diltiazem hcl cr | Diltiazem hcl flx | Diltiazem HCl sandoz | Diltiazem hcl teva | Surazem | Tiadil | Tildiem | Tildiem lp | Viazem;
  • (NO) Norway: Cardizem | Cardizem Retard | Diltiazem | Diltiazem ratiopharm | Diltikard | Kardil | Tildiem | Tildiem la | Tilker;
  • (NZ) New Zealand: Apo Diltiazem | Cardizem | Cardizem cd | Dilacor XR | Dilcard | Diltiazem cd | Diltiazem HCL | Dilzem;
  • (PE) Peru: Diltiazem | Diltiazen clorhidrato | Dodexen | Dodexen ap | Grifodilzem | Incoril | Tilazem;
  • (PH) Philippines: Angiozem | Cordazem | Dilatam | Dilcardia | Diltac | Diltelan | Diltiazem | Diltiazem Pacific | Dilzem | Dyalac | Forzem | Novoptin | Sandizem | Servazen | Tildiem | Vasmulax | Zandil | Zemdil;
  • (PK) Pakistan: Angizem | Calcard | Calcicor | Calzem | Cardiazem | Dazil | Deltazem | Desbon | Diacord | Diltiazaf | Dilzem | Dtz | Etizem | Herbesser | Lacerol | Locard | Metazem | Perlita sr | Procard | Quzem | Tiazem | Zem | Zemycard;
  • (PL) Poland: Aldizem | Apo diltiaz | Blocalcin | Diacordin | Dilocard | Dilrene lp | Diltiazem | Diltiazem HCL | Dilzem | Entrydil | Oxycardil | Poltiazem | Tildiem | Zilden;
  • (PR) Puerto Rico: Cardizem | Cardizem cd | Cardizem la | Cartia xt | Dilacor XR | Dilt-xr | Diltia | Diltiazem | Diltiazem 12hr | Diltiazem cd | Diltiazem HCL | Diltiazem Hcl cd | Diltiazem HCL extended release | Diltiazem hydrochloride extended release | Diltiazem xr | Diltzac | Taztia xt | Tiadylt er | Tiazac;
  • (PT) Portugal: Alandiem | Altiazem | Balcor | Cal-antagon | Dilfar | Dilongo | Diltiangina | Diltiazem | Diltiazem sandoz | Diltiem | Duplide | Etizem | Herbesser | Pentilzeno | Tiadil;
  • (PY) Paraguay: Acalix | Acalix cd | Angiten | Cardizen | Diltiazem prosalud | Hart | Hart a.p. | Incoril | Incoril ap | Incoril monodosis | Nortenol;
  • (QA) Qatar: Adizem-XL | Apo-Diltiaz | Bi-Tildiem | Diltizem SR | Dilzem | Dilzem Retard | Mono-Tildiem | Riazem | Tildiem;
  • (RO) Romania: Aldizem | Altiazem rr | Asdilt | Blocalcin | Cardil | Diacordin | Dilatam | Diltiazem | Diltiazem arena | Diltiazem bioeel | Diltiazem eipico | Diltiazem lph | Diltiazem sr rompharm | Diltisan | Diltizem | Dilzem;
  • (RU) Russian Federation: Aldizem | Altiazem rr | Angizem | Cardil | Diacordin | Diazem | Dilrene | Diltiazem | Diltiazem Lannacher | Diltiazem ratiopharm | Diltizem | Dilzem;
  • (SA) Saudi Arabia: Apo diltaz | Bi tildiem | Dilzem | Monotildiem | Riazem | Tildiem;
  • (SE) Sweden: Cardizem | Cardizem Retard | Coramil | Diltelan | Diltikard;
  • (SG) Singapore: Angizem | Beatizem | Cardil | Cardium | Herbesser | Mono-tildiem;
  • (SI) Slovenia: Aldizem | Diltiazem | Dilzem;
  • (SK) Slovakia: Altiazem rr | Blocalcin | Diacordin | Dilrene lp | Dilzem;
  • (TH) Thailand: Altiazem | Angizem | Apo diltiaz | Cardiazem | Cardil | Carzem | Cascor | Denazox | Dilatam | Dilcardia | Dilem | Dilizem | Diltiazem | Ditizem | Herbesser | Herbesser 90 | Herbesser r | Herbie | Medozem | Progor | Seresnatt | Tildiem;
  • (TN) Tunisia: Altiazem | Bi tildiem | Cardiadil | Dilrene | Dipen | Mono tiazem lp | Mono-tildiem | Tildiem | Zilden;
  • (TR) Turkey: Altizem | Dilticard | Diltizem | Progor | Tiacard;
  • (TW) Taiwan: Aerisin | Altiazem | Angeltension | Calnurs | Cardil | Cardizem | Cartil | Coroherser | Dilazem | Dilem | Diltahexal | Diltelan | Diltiazem | Diltisser | Dilzem | Diyazen | Etizem | Hagen | Herbesser | Herzen | Hesor | Latiazem | Miocardie | Miocaride | Nakasser | Pertiazem | Progor | Seresnatt | Silzem | Suboshin | Tazem | Tiaves | Yohtiazem;
  • (UA) Ukraine: Aldizem | Angizem | Cardil | Diacardil | Diacordin retard | Dilrene | Diltiazem | Diltiazem alkaloid | Diltisan | Retalzem;
  • (UG) Uganda: Dilcontin;
  • (UY) Uruguay: Cirilen | Cirilen CD | Dilangin | Diltiasur | Diltiazem | Dilzem | Grifodilzem | Incoril | Kardiozem | Tilazem;
  • (VE) Venezuela, Bolivarian Republic of: Acalix | Corazem | Cordisil | Daltazen | Diltiazem | Distiazem | Presoquin | Tilazem;
  • (VN) Viet Nam: Bidizem | Bidizem mr | Diltiazem stella | Tilhasan | Tilhazem;
  • (ZA) South Africa: Diatil | Dilatam | Rolab-diltiazem | Tilazem | Zildem
  1. AA-Diltiaz (diltiazem) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; April 2020.
  2. Ahmad S. Diltiazem myopathy. Am Heart J. 1993;126(6):1494‐1495. doi:10.1016/0002-8703(93)90572-q [PubMed 8249821]
  3. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2018;138(13):e419-e420]. Circulation. 2018;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549. [PubMed 29084731]
  4. Allen LV Jr, Erickson MA 3rd. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health Syst Pharm. 1996;53(18):2179-2184. [PubMed 8879325]
  5. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. [PubMed 30575676]
  6. Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718]
  7. Andrivet P, Beaslay V, Kiger JP, vu Gnoc C. Complete sinus arrest during diltiazem therapy; clinical correlates and efficacy of intravenous calcium. Eur Heart J. 1994;15(3):350‐354. doi:10.1093/oxfordjournals.eurheartj.a060502 [PubMed 8013508]
  8. Apo-Diltiaz (diltiazem) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; September 2018.
  9. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [published corrections appear in Circulation. 2011;123(21):e616; Circulation. 2011;124(5):e175; Circulation 2016;133(24):e715]. Circulation. 2011;123(21):2434-2506. [PubMed 21518977]
  10. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928. [PubMed 17565025]
  11. Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. Drug Saf. 2019;42(8):973‐992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
  12. Beltrame JF, Crea F. Vasospastic angina. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 11, 2019.
  13. Bertorini TE, Palmieri GMA, Griffin JW, et al. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy. Neurology. 1988;38(4):609-613. [PubMed 3281058]
  14. Bowman JM, Levy BA, Grubb RV. Gingival overgrowth induced by diltiazem. A case report. Oral Surg Oral Med Oral Pathol. 1988;65(2):183‐185. doi:10.1016/0030-4220(88)90163-6 [PubMed 3422722]
  15. Brenes JA, Cha YM. Diltiazem-induced transient complete atrioventricular block in an elderly patient with acute on chronic renal failure. Open Cardiovasc Med J. 2013;7:23‐26. doi:10.2174/1874192401307010023 [PubMed 23847692]
  16. Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74(1):14‐27. doi:10.1111/all.13562 [PubMed 30028512]
  17. Campbell M, Ahluwalia J, Watson AC. Diltiazem-associated hyperpigmentation. J Gen Intern Med. 2013;28(12):1676. doi:10.1007/s11606-013-2530-1 [PubMed 23846341]
  18. Cardizem (diltiazem hydrochloride) tablets [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; June 2020.
  19. Cardizem (diltiazem hydrochloride) capsules [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; January 2017.
  20. Cardizem (diltiazem hydrochloride) direct compression tablets [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2014.
  21. Cardizem CD (diltiazem hydrochloride) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; April 2020.
  22. Cardizem CD (diltiazem hydrochloride) [product monograph]. Laval, Quebec, Canada: Bausch Health Canada Inc; June 2022.
  23. Cardizem LA (diltiazem hydrochloride) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; September 2019.
  24. Cartia XT (diltiazem hydrochloride) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; August 2020.
  25. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289(19):2560-2572. [PubMed 12748199]
  26. Cholez C, Trechot P, Schmutz JL, Faure G, Bene MC, Barbaud A. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. Allergy. 2003;58(11):1207‐1209. doi:10.1034/j.1398-9995.2003.00222.x [PubMed 14616146]
  27. Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082 [PubMed 31841131]
  28. Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med. 1995;333(21):1429. [PubMed 7477141]
  29. Deng W, Farricielli L. Hypoxic hepatitis and acute liver failure in a patient with newly onset atrial fibrillation and diltiazem infusion. BMJ Case Rep. 2013;2013:bcr2013200573. doi:10.1136/bcr-2013-200573 [PubMed 24042208]
  30. Dilt-XR (diltiazem) [prescribing information]. Weston, FL: Apotex; July 2012.
  31. Diltiazem extended-release capsules, USP [prescribing information]. Memphis, TN: Northstar Rx LLC; June 2022.
  32. Diltiazem injection [prescribing information]. E Windsor, NJ: Eugia US LLC; April 2023.
  33. Diltiazem injection [product monograph]. Montreal, Quebec, Canada: Omega Laboratories Limited; March 2021.
  34. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet. 1986;11(6):425-449. doi:10.2165/00003088-198611060-00002 [PubMed 3542336]
  35. Edoute Y, Nagachandran P, Svirski B, Ben-Ami H. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol. 2000;35(4):556‐559. doi:10.1097/00005344-200004000-00007 [PubMed 10774785]
  36. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18(4):891-897. doi:10.1016/0735-1097(91)90743-s [PubMed 1894861]
  37. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  38. Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):640-656. [PubMed 20956217]
  39. Flynn JT, Pasko DA. Calcium channel blockers: Pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol. 2000;15(3-4):302-316. [PubMed 11149130]
  40. Friedland S, Kaplan S, Lahav M, Shapiro A. Proptosis and periorbital edema due to diltiazem treatment. Arch Ophthalmol. 1993;111(8):1027‐1028. doi:10.1001/archopht.1993.01090080023010 [PubMed 8352682]
  41. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006;48(4):854-906. [PubMed 16904574]
  42. Gesierich A, Rose C, Brocker EB, Trautmann A, Leverkus M. Acute generalised exanthematous pustulosis with subepidermal blisters of the distal extremities induced by diltiazem. Dermatology. 2006;213(1):48‐49. doi:10.1159/000092840 [PubMed 16778429]
  43. Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159-168. [PubMed 12570960]
  44. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction with non-Q-wave myocardial infarction. N Engl J Med. 1986;315(7):423-429. [PubMed 3526151]
  45. Gill JS, Ward DE, Camm JA. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15(11, pt 2):2122-2126. [PubMed 1279611]
  46. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published correction appears in Hypertension. 2014 Jun;63(6):e175]. Hypertension. 2014;63(4):878‐885. doi:10.1161/HYP.0000000000000003 [PubMed 24243703]
  47. Gonzalo Garijo MA, Pérez Calderón R, de Argila Fernández-Durán D, Rangel Mayoral JF. Cutaneous reactions due to diltiazem and cross reactivity with other calcium channel blockers. Allergol Immunopathol (Madr). 2005;33(4):238‐240. doi:10.1157/13077752 [PubMed 16045866]
  48. Grech-Bélanger O, Langlois S, LeBoeuf E. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol. 1988;28(5):477-480. doi:10.1002/j.1552-4604.1988.tb05763.x [PubMed 3392246]
  49. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
  50. Hill K, Sucha E, Rhodes E, et al. Amiodarone, verapamil, or diltiazem use with direct oral anticoagulants and the risk of hemorrhage in older adults. CJC Open. 2021;4(3):315-323. doi:10.1016/j.cjco.2021.11.002 [PubMed 35386137]
  51. Hossack KF. Conduction abnormalities due to diltiazem. N Engl J Med. 1982;307(15):953‐954. doi:10.1056/nejm198210073071516 [PubMed 7110278]
  52. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237 [PubMed 36017548]
  53. Imamura T, Koiwaya Y, Nakamura M. Sinoatrial block induced by oral diltiazem. Clin Cardiol. 1986;9(1):33‐34. doi:10.1002/clc.4960090108 [PubMed 3943233]
  54. Inui S, Itami S, Yoshikawa K. A case of lichenoid purpura possibly caused by diltiazem hydrochloride. J Dermatol. 2001;28(2):100‐102. doi:10.1111/j.1346-8138.2001.tb00098.x [PubMed 11320702]
  55. Ishikawa T, Imamura T, Koiwaya Y, Tanaka K. Atrioventricular dissociation and sinus arrest induced by oral diltiazem. N Engl J Med. 1983;309(18):1124‐1125. doi:10.1056/NEJM198311033091813 [PubMed 6621654]
  56. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. [PubMed 24352797]
  57. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193 [PubMed 38033089]
  58. Kannam JP, Aroesty JM, Gersh BJ. Calcium channel blockers in the management of stable angina pectoris. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 11, 2019.
  59. Kaplan R. Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 28, 2024.
  60. Kitamura K, Kanasashi M, Suga C, Saito S, Yoshida S, Ikezawa Z. Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions. J Dermatol. 1993;20(5):279‐286. doi:10.1111/j.1346-8138.1993.tb01392.x [PubMed 8340532]
  61. Kjeldsen SE, Syvertsen JO, Hedner T. Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. Blood Press. 1996;5(5):260‐263. doi:10.3109/08037059609078057 [PubMed 8879597]
  62. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):876-908. [PubMed 20956230]
  63. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586. doi: 10.1016/j.chest.2018.11.030. [PubMed 30660783]
  64. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. J Am Acad Dermatol. 1998;38(2 Pt 1):201‐206. doi:10.1016/s0190-9622(98)70241-5 [PubMed 9486675]
  65. Koskinas KC, Lillis L, Ziakas A. Diltiazem: a reversible cause of atrioventricular block - until proven otherwise. Open Cardiovasc Med J. 2013;7:46. doi:10.2174/1874192401307010046 [PubMed 23878619]
  66. Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol. 2010;37(9):807‐811. doi:10.1111/j.1346-8138.2010.00858.x [PubMed 20883365]
  67. Lee WK, Shameem M, Ganti L, Banerjee PR, Shivdat J. Cardiac arrest following treatment with diltiazem for atrial fibrillation with rapid ventricular response. Cureus. 2020;12(11):e11678. doi:10.7759/cureus.11678 [PubMed 33391915]
  68. Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
  69. Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 7, 2023.
  70. Manolis AS. Premature ventricular complexes: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 16, 2019.
  71. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-1713. [PubMed 14607462]
  72. Matzim LA (diltiazem) [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; January 2024. [PubMed 14607462]
  73. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619. doi: 10.1016/j.jacc.2009.01.004. [PubMed 19389575]
  74. Michalets EL, Jackson DV. Diltiazem-associated thrombocytopenia. Pharmacotherapy. 1997;17(6):1345‐1348. [PubMed 9399624]
  75. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15):1898-1907. doi: 10.1093/eurheartj/ehq170. [PubMed 20543192]
  76. Morgan JP. Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 27, 2022.
  77. Moser LR, Panacek EA, Munger MA. Fatality due to intravenous diltiazem for acute ventricular rate control. Pharmacotherapy. 1996;16(2):306‐310. [PubMed 8820477]
  78. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
  79. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published correction appears in Circulation. 2011;123(6):e236. Circulation. 2013;128(25):e480]. Circulation. 2010;122(18)(suppl 3):S729-S767. doi: 10.1161/CIRCULATIONAHA.110.970988. [PubMed 20956224]
  80. Odeh M. Exfoliative dermatitis associated with diltiazem. J Toxicol Clin Toxicol. 1997;35(1):101‐104. doi:10.3109/15563659709001174 [PubMed 9022661]
  81. Okada M, Inoue H, Nakamura Y, et al. Excretion of Diltiazem in Human Milk. N Engl J Med. 1985;312(15):992-993. [PubMed 3974691]
  82. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y [PubMed 37256475]
  83. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045 [PubMed 33229116]
  84. Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. Pacing Clin Electrophysiol. 2012;35(7):804‐810. doi:10.1111/j.1540-8159.2012.03410.x [PubMed 22530749]
  85. Page RL, Joglar JA, Caldwell MA, et al; Evidence Review Committee Chair. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2016;134(11):e234-e235]. Circulation. 2016;133(14):e506-e574. doi: 10.1161/CIR.0000000000000311. [PubMed 26399663]
  86. Park, MK. Park's Pediatric Cardiology for Practitioners. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.
  87. Pass RH, Liberman L, Al-Fayaddh M, et al. Continuous Intravenous Diltiazem Infusion for Short-Term Ventricular Rate Control in Children. Am J Cardiol. 2000;86(5):559-62, A9. [PubMed 11009280]
  88. Perozo MA, Escaño L, Thompson R, Cedeno H. A rare case of diltiazem-induced photosensitivity. Cureus. 2023;15(6):e40376. doi:10.7759/cureus.40376 [PubMed 37456398]
  89. Pham P, Schmidt S, Lesko L, Lip GYH, Brown JD. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open. 2020;3(4):e203593. doi:10.1001/jamanetworkopen.2020.3593 [PubMed 32329770]
  90. Pozet N, Brazier JL, Aïssa AH, et al. Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol. 1983;24(5):635-638. doi:10.1007/BF00542213 [PubMed 6873142]
  91. Prutkin JM. Overview of the acute management of tachyarrhythmias. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 21, 2022.
  92. Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. J Clin Pharmacol. 1988;28(1):6‐21. doi:10.1002/j.1552-4604.1988.tb03095.x [PubMed 2450898]
  93. Ramírez A, Pérez-Pérez L, Fernández-Redondo V, Toribio J. Photoallergic dermatitis induced by diltiazem. Contact Dermatitis. 2007;56(2):118‐119. doi:10.1111/j.1600-0536.2007.00967.x [PubMed 17244089]
  94. Refer to manufacturer's labeling.
  95. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. [PubMed 30165544]
  96. Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015;9(6):453-498. [PubMed 25840695]
  97. Sáenz de Santa María García M, Noguerado-Mellado B, Rojas Pérez-Ezquerra P, Hernandez-Aragües I, De Barrio Fernández M. Acute generalized exanthematous pustulosis due to diltiazem: Investigation of cross-reactivity with other calcium channel blockers. J Allergy Clin Immunol Pract. 2016;4(4):765‐766. doi:10.1016/j.jaip.2016.02.004 [PubMed 27025295]
  98. Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991;14(4):314‐316. doi:10.1002/clc.4960140406 [PubMed 1674455]
  99. Saladi RN, Cohen SR, Phelps RG, Persaud AN, Rudikoff D. Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature. Arch Dermatol. 2006;142(2):206‐210. doi:10.1001/archderm.142.2.206 [PubMed 16490848]
  100. Sanders CJ, Neumann HA. Erythema multiforme, Stevens-Johnson syndrome, and diltiazem. Lancet. 1993;341(8850):967. doi:10.1016/0140-6736(93)91264-m [PubMed 8096307]
  101. Shallcross H, Padley SP, Glynn MJ, Gibbs DD. Fatal renal and hepatic toxicity after treatment with diltiazem. Br Med J (Clin Res Ed). 1987;295(6608):1236‐1237. doi:10.1136/bmj.295.6608.1236 [PubMed 3120959]
  102. Sheehan-Dare RA, Goodfield MJ. Widespread cutaneous vasculitis associated with diltiazem. Postgrad Med J. 1988;64(752):467‐468. doi:10.1136/pgmj.64.752.467 [PubMed 3211830]
  103. Shurrab M, Jackevicius CA, Austin PC, et al. Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients. J Interv Card Electrophysiol. 2023;66(3):629-635. doi:10.1007/s10840-022-01355-1 [PubMed 36149579]
  104. Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens. 2003;12(2):123-131. doi:10.1097/00041552-200303000-00001 [PubMed 12589171]
  105. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989‐996. doi:10.1111/j.1365-2133.2007.08156.x [PubMed 17854366]
  106. Siegel JD, Ko CJ. Diltiazem-associated photodistributed hyperpigmentation. Yale J Biol Med. 2020;93(1):45-47. [PubMed 32226335]
  107. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-3111. doi: 10.1161/CIRCULATIONAHA.104.488486. [PubMed 15939821]
  108. Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. Published online October 5, 2021. doi:10.1111/bcp.15060 [PubMed 34611920]
  109. Sousa-Basto A, Azenha A, Duarte ML, Pardal-Oliveira F. Generalized cutaneous reaction to diltiazem. Contact Dermatitis. 1993;29(1):44‐45. doi:10.1111/j.1600-0536.1993.tb04541.x [PubMed 8365158]
  110. Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139(1):45-49. [PubMed 12533163]
  111. Steele RM, Schuna AA, and Schreiber RT. Calcium Antagonist-Induced Gingival Hyperplasia. Ann Intern Med. 1994;120(8):663-664. [PubMed 8135450]
  112. Stern R, Khalsa JH. Cutaneous adverse reactions associated with calcium channel blockers. Arch Intern Med. 1989;149(4):829‐832. [PubMed 2523214]
  113. Subahi A, Ibrahim W, Abugroun A. Diltiazem-associated cardiogenic shock in thyrotoxic crisis. Am J Ther. 2018;25(6):e666‐e669. doi:10.1097/MJT.0000000000000739 [PubMed 29521654]
  114. Tawashi M, Marc-Aurèle J, Bichet D, et al. Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers. Biopharm Drug Dispos. 1991b;12(2):105-112. doi:10.1002/bdd.2510120203 [PubMed 2031991]
  115. Tawashi M, Marc-Aurèle J, Bichet D, et al. Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure. Biopharm Drug Dispos. 1991a;12(2):95-104. doi:10.1002/bdd.2510120202 [PubMed 2031997]
  116. Taylor JW, Cleary JD, Atkinson RC. Stevens-Johnson syndrome associated with diltiazem. Clin Pharm. 1990;9(12):948‐950. [PubMed 2292178]
  117. Taztia (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; June 2014.
  118. Taztia XT (diltiazem) [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; October 2017.
  119. Tiazac (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant; November 2016.
  120. Tiazac (diltiazem) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; July 2020.
  121. Tiazac XC (diltiazem) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; February 2023.
  122. Tuchinda P, Kulthanan K, Khankham S, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to calcium channel blockers. Asian Pac J Allergy Immunol. 2014;32(3):246‐250. doi:10.12932/AP0380.32.3.2014 [PubMed 25268343]
  123. Vicente-Calleja JM, Aguirre A, Landa N, Crespo V, González-Pérez R, Díaz-Pérez JL. Acute generalized exanthematous pustulosis due to diltiazem: confirmation by patch testing. Br J Dermatol. 1997;137(5):837‐839. doi:10.1111/j.1365-2133.1997.tb01139.x [PubMed 9415262]
  124. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168 [PubMed 37471501]
  125. Waller PC, Inman WH. Diltiazem and heart block. Lancet. 1989;1(8638):617. doi:10.1016/s0140-6736(89)91644-9 [PubMed 2564139]
  126. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26. [PubMed 24341872]
  127. Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol. 1986;57(1):6-9. [PubMed 3510525]
  128. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018;71(6):e140-e144]. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. [PubMed 29133356]
  129. Wittal RA, Fischer GO, Georgouras KE, Baird PJ. Skin reactions to diltiazem [published correction appears in Australas J Dermatol 1992;33(2):86]. Australas J Dermatol. 1992;33(1):11‐18. doi:10.1111/j.1440-0960.1992.tb00047.x [PubMed 1445088]
  130. Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. J Am Coll Cardiol. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057 [PubMed 15234417]
  131. Zimetbaum PJ, Wylie JV. Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 4, 2019.
Topic 9365 Version 838.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟